Frequently asked questions about TIGLUTIK

Ask your doctor if TIGLUTIK is right for you. Be sure to discuss all of the medications you are taking with your doctor or healthcare team.

Q: Is there a co-pay program available with TIGLUTIK?

A: Financial support is available with TIGLUTIK. The TIGLUTIK co-pay assistance program enables those who are prescribed TIGLUTIK to access the treatment for no more than $50 per filled prescription of TIGLUTIK.*

Q: Is TIGLUTIK the same drug as riluzole?

A: The active ingredient in TIGLUTIK is riluzole. Riluzole has been available in tablet form for more than 20 years to treat ALS. However, TIGLUTIK is a liquid, which is a different form of riluzole, designed specifically to address swallowing issues in people living with ALS.

Q: Is TIGLUTIK different from Rilutek?

A: The active ingredient in TIGLUTIK and Rilutek is riluzole. However, TIGLUTIK is different from Rilutek because it was designed specifically to address swallowing issues in people living with ALS. Because TIGLUTIK is a liquid form of riluzole, it’s easy to swallow at all stages of ALS.

Q: Can TIGLUTIK be taken with Radicava®?

A: Ask your healthcare provider about any medications that you take with TIGLUTIK.

Q: How is TIGLUTIK taken?

A: TIGLUTIK 50 mg (10 mL) is taken twice daily, once in the morning and once in the evening, using the oral syringes provided with the prescription.

Q: Can TIGLUTIK be mixed with food?

A: TIGLUTIK is an easy-to-swallow liquid form of riluzole. Just like riluzole tablets, the prescribing information clearly states that it should not be mixed with food as that may change how your body absorbs the medicine. TIGLUTIK should be taken or administered through the syringes provided with the TIGLUTIK prescription.

Q: Does TIGLUTIK have to be taken with food?

A: Just like riluzole tablets, the prescribing information states that TIGLUTIK should be taken at least one hour before or two hours after a meal.

Q: Is TIGLUTIK covered by insurance?

A: TIGLUTIK should be covered by most commercial insurance plans. Eligible patients will pay no more than $50 per filled prescription of TIGLUTIK.* Veterans should have access to TIGLUTIK through the Department of Veterans Affairs (VA).

Q: How long has TIGLUTIK been used by people with ALS?

A: Riluzole, the active ingredient in TIGLUTIK, has been used in people with ALS for more than 20 years.

Q: When can I start treatment with TIGLUTIK?

A: TIGLUTIK should be taken as prescribed by your doctor. Treatment with TIGLUTIK should be started as early as diagnosis and throughout the course of treatment of ALS.

Q: Was TIGLUTIK studied in different forms of ALS?

A: People with both familial ALS (the type with a genetic connection) and sporadic ALS were studied in the clinical trials. TIGLUTIK was effective at extending survival, regardless of the type of ALS.

Q: How effective is riluzole?

A: Riluzole has established its effectiveness since its FDA approval in 1995 and through years of patient use in clinical trials. In 2 clinical studies with more than 1,100 people with ALS, progression was slowed in those who took riluzole versus a sugar pill (also known as a placebo).

Q: How does riluzole work?

A: The mechanism by which riluzole exerts its therapeutic effects in patients with ALS is unknown. Riluzole, the active ingredient in TIGLUTIK, has been studied in 2 clinical trials. It is proven to slow the progression of disease. In clinical studies, people who took riluzole versus those who took a sugar pill (also known as a placebo) had extended survival by up to 3 months. Clinical outcomes were based on time to tracheostomy or death.

Radicava is a registered trademark of Mitsubishi Tanabe Pharma America, Inc.

Offer is valid for each prescription fill for commercially insured patients where TIGLUTIK is covered. Offer is valid for patients age 18 and older. Medicare, Medicaid, TRICARE, or other patients of other federal or state programs are not eligible. ITF Pharma reserves the right to rescind, revoke, or amend this offer without notice. Offer good only in the USA, including Puerto Rico, at participating retail pharmacies. Void if prohibited by law, taxed, or restricted. This offer has no cash value and may not be used in combination with any other discount, coupon, rebate, free trial, or similar offer for the specified product. Maximum savings limit applies; patient out-of-pocket expense may vary.

Doctor Discussion Guide

Download now

TIGLUTIK co-pay support is available*

Learn more



TIGLUTIK (riluzole) is a prescription medicine for the treatment of amyotrophic lateral sclerosis (ALS).

Important Safety Information

  • You should not take TIGLUTIK if you are allergic to any of its ingredients.
  • TIGLUTIK can cause liver injury, including death. Your doctor should do blood tests to check your liver function before and during your treatment and may stop treatment with TIGLUTIK if liver function is not normal. Contact your doctor immediately if you have unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine.
  • Call your doctor immediately if you have a fever, cough, or difficulty in breathing while taking TIGLUTIK.
  • If you miss or skip a dose of TIGLUTIK, do not take any extra dose to make up for those you missed, but take your prescribed dose at the next regularly scheduled time.
  • The most common side effects of TIGLUTIK that occurred during medical studies were numbness/tingling around the mouth, weakness, nausea, decreased lung function, high blood pressure, and abdominal pain. If any side effects become troublesome, contact your doctor.
  • Be sure to tell your doctor and pharmacist about all other health conditions you have and all medicines you are taking, including nonprescription products and vitamins. If you have questions, please talk to your doctor.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-332-1088.

Please click here for the Full Prescribing Information.